Cingulate Inc

NASDAQ:CING

Business Description

Sector

Health Care

Industry

Pharmaceuticals

Headquarters

United States of America US

Employees

14

IPO date

Oct 7, 2021

Cingulate is a clinical-stage pharmaceutical company that develops prescription medicines using its own timed-release drug delivery technology. Its main work is creating oral drugs that release medicine in a controlled pattern over the day, with a focus on attention deficit hyperactivity disorder and other central nervous system conditions. The company is still in development, so it is not a broad drug seller; its value comes from moving candidate medicines through testing and approval.

Its lead programs are built around a platform designed to give patients a smoother, longer-lasting effect from a single daily dose. In simple terms, Cingulate sells the idea of better dosing and more predictable medicine timing, not a large catalog of approved drugs. The main customers it ultimately seeks are patients, doctors, and, through partnerships, larger pharmaceutical companies that may help commercialize its products.

Cingulate makes money mainly by advancing its drug candidates, securing development or licensing partnerships, and eventually earning product sales or royalty income if any candidate reaches the market. What makes the business different is that it sits at the intersection of drug development and delivery technology: it is trying to improve how an existing medicine works by changing when it is released in the body, rather than inventing an entirely new chemical from scratch.